← Back to Search

Procedure

AblaCare System for Polycystic Ovary Syndrome (ULTRA-US Trial)

N/A
Waitlist Available
Research Sponsored by May Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing the safety and effectiveness of the AblaCare System, a device that helps doctors remove small parts of the ovary using ultrasound, in women with PCOS who have trouble getting pregnant and haven't had success with other treatments.

Eligible Conditions
  • Polycystic Ovary Syndrome
  • Female Infertility

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Experimental Treatment
Group I: AblaCare ProcedureExperimental Treatment1 Intervention
AblaCare Procedure performed with use of the AblaCare Kit intended for transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to polycystic ovary syndrome.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AblaCare System
2022
N/A
~10

Find a Location

Who is running the clinical trial?

May HealthLead Sponsor
2 Previous Clinical Trials
223 Total Patients Enrolled
2 Trials studying Polycystic Ovary Syndrome
223 Patients Enrolled for Polycystic Ovary Syndrome
AblaCareLead Sponsor
1 Previous Clinical Trials
28 Total Patients Enrolled
1 Trials studying Polycystic Ovary Syndrome
28 Patients Enrolled for Polycystic Ovary Syndrome

Media Library

AblaCare System (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05320289 — N/A
Polycystic Ovary Syndrome Research Study Groups: AblaCare Procedure
Polycystic Ovary Syndrome Clinical Trial 2023: AblaCare System Highlights & Side Effects. Trial Name: NCT05320289 — N/A
AblaCare System (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05320289 — N/A
~1 spots leftby Oct 2025